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C
linical research across the spectrum of human dis-
ease is challenged by the immense cost of testing
experimental therapeutics in human subjects. In
every subspecialty of medicine, there is a need for surro-
gate markers of disease for the purposes of identifying
subjects at risk, documenting ‘‘target engagement’’ and
objectifying treatment outcomes in a manner that will
permit ‘‘proof of concept’’ trials with feasible numbers of
subjects and a reasonable duration of treatment. A targe-
ted approach to identification and validation of such
biomarkers has been successful in some arenas, such as the
use of glycosylated haemoglobin for monitoring diabetes
mellitus or use of quantitative viral load for monitoring
HIV therapy. Non-targeted empirical approaches using
proteomics and metabolomics have also seen some suc-
cess, so it follows logically that microRNAs (miRNAs) are
now being evaluated as biomarkers in a variety of human
diseases. It remains to be seen whether miRNAs will be

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more informative or more useful than protein biomarkers,
particularly as new methodologies make it possible to
focus on exosomal proteins rather than total protein, and
on exosomes derived from specific organs (1). A discussion
of the utility of exosomal protein biomarkers is beyond the
scope of this review, but the emphasis here on miRNA
should not be interpreted as a conclusion that we have
no more to learn from protein biomarkers. The focus on
miRNAs is simply a reflection of the nature of the con-
sortium being reviewed here. As described elsewhere in
this issue, the NIH Common Fund Extracellular RNA
Communication Program has funded 10 UH2/UH3 grants
to identify extracellular RNA (exRNA) biomarkers in
conditions ranging from gastric cancer to Alzheimer’s
disease (AD), relying on body fluids ranging from saliva to
cerebrospinal fluid (CSF). This funding mechanism is
relatively unique within the NIH, funding ‘‘high risk,’’
‘‘discovery’’ work over the first 2 years in a ‘‘UH2’’ phase,
with each project advancing to more traditional NIH-
funded hypothesis testing in years 35 of ‘‘UH3’’ funding,
dependent on the attainment of predefined milestones.
Each of these projects is currently in a ‘‘discovery’’ phase
after about 1 year of activity. We review here the rationale,
methods and progress of the UH2 projects, summarized in
Table I. Both the table and the following text are listed
according to organ system studied and the relevant body
fluid analyzed, as depicted in Fig. 1. Since clinical phe-
notyping of the samples is so critical to the success of the
projects, the clinical cohort for each is also indicated.
Biomarkers of cancer
Even laypeople are familiar with the use of serum
prostate specific antigen as a useful biomarker for both
detection and response to therapy of prostate cancer, and
several other protein biomarkers of cancer are currently
employed, so it follows that miRNA biomarkers might be
used productively in oncology. Two of the funded grants
focus on identification of miRNA biomarkers of cancer,
in hepatocellular and gastric cancer, respectively.
Biomarkers of hepatocellular cancer
In ‘‘Extracellular Non-Coding RNA Biomarkers of Hepa-
tocellular Cancer’’ (TR000884), Dr. Patel and colleagues
at Mayo Clinic Jacksonville Florida are studying plasma
biomarkers of hepatocellular carcinoma (HCC), making
the point that HCC is the second most common cancer
world-wide, with a global incidence of 750,000 new
patients per year. The incidence of these cancers has been
increasing in the United States as a consequence of the
epidemics of chronic hepatitis C virus infection, obesity
and non-alcoholic steatohepatitis increasing the preva-
lence of cirrhosis, which is the most important risk factor
for HCC. Survival from this cancer remains poor, despite
the fact that the population at risk (cirrhosis patients) is
readily identified. Early diagnosis can reduce mortality of
HCC, as resection and liver transplantation can be cura-
tive if disease is sufficiently localized when diagnosed. For
example, the 5-year recurrence-free survival in patients
with small tumours without macroscopic vascular invasion
is over 80%. However, most patients with HCC are diag-
nosed at an advanced stage when these surgical procedures
cannot be performed, and the survival of patients with
HCC continues to be grim with 1- and 3-year survival
rates of 29 and 8%. Screening and surveillance for HCC
in patients at risk can consequently reduce mortality from
HCC by early diagnosis, but the currently available bio-
markers are not adequate. For example, the currently
used tumour marker, alpha-fetoprotein (AFP), is elevated
in less than 50% of HCC patients. Other blood-based bio-
markers such as des-gamma-carboxy prothrombin (DCP)
and lectin-reactive alpha-fetoprotein (AFP-L3) also lack
the sensitivity to sufficiently detect early stage cancer amen-
able to surgical cure. Preliminary studies have demon-
strated the feasibility of developing miRNA biomarkers
of HCC by documenting miRNA dysregulation in these
cancers (2,3), and by demonstrating exRNA in the cir-
culation of persons with HCC (4).
Biomarkers of hepatocellular cancer: approach
The overall goals of this project are to identify and
qualify circulating exRNA-based biomarkers in order to
detect early stage HCC in patients at risk and to monitor
response to therapy. A two-phase biomarker development
approach is being undertaken. The goal of the first UH2
phase is to identify and develop assays for exRNA can-
didates with potential for further study as biomarkers for
HCC, whereas the goals of the second UH3 phase will
be to validate the clinical utility of promising exRNA
candidates identified from the first phase.
Biomarkers of hepatocellular cancer: progress to date
A systematic search to identify, characterize and quantify
long intergenic non-coding RNAs (lincRNAs) that are
expressed in HCC, and non-coding exRNA that are selec-
tively associated with HCC cells has been performed. To
identify lincRNA associated with HCC, whole transcrip-
tome deep-sequencing data from HCC samples obtained
through The Cancer Genome Atlas were analyzed using a
custom-derivedbioinformaticspipeline.CandidatelincRNAs
were further examined for evidence of transcriptional
activity using the H3K4me3-H3K36me3 domains gen-
erated from the ENCODE project. Studies to date have
identified candidate exRNA that are released by HCC cells
in culture and can be detected in the circulation in patients
with HCC. The expression of both miRNA and a selected
panel of long ncRNA has been examined in a panel of both
non-malignant (HH and THLE-2 cells) and malignant
(Hep3B, HepG2, PLC/PRF/5, SNU-182 and SNU-398)
hepatocytes, and in extracellular vesicles (EVs) released
from these cells in culture. These screening profiling studies
were done using quantitative polymerase chain reaction
Joseph F. Quinn et al.
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Table I. ERCC biomarker projects
PI(s)/site Grant title Organ system/biofluid Clinical cohort
Patel/Mayo Clinic Jacksonville Extracellular Non-Coding RNA Biomarkers of
Hepatocellular Cancer
Hepatobiliary/serum and
plasma
Mayo Hepatobiliary Neoplasia Biorepository
Wong/UCLA Clinical Utility of Salivary ExRNA Biomarkers
of Gastric Cancer Detection
Gastrointestinal/saliva UCLA PRoBE
Das/Beth Israel Deaconess Plasma miRNA Predictors of Adverse
Mechanical and Electrical Modeling after MI
Cardiac/plasma PROSPECT-CMR Cohort; Thrombolysis in Myocardial
Infarction (TIMI)
Freedman/University of Massachusetts Extracellular RNAs  Biomarkers for
Cardiovascular Risk and Disease
Cardiac/plasma Framingham Heart Study
Laurent/University of California San Diego ExRNAs for Early Identification of
Pregnancies at Risk for Placental Dysfunction
Placenta/serum UCSD Placental Dysfunction Study; PAPR Cohort from
Sera Prognostics
Saugstad, Quinn/Oregon Health & Science
University
Clinical Utility of MicroRNAs As Diagnostic
Biomarkers of Alzheimer’s Disease
Central nervous system/
CSF
Oregon ADC Biorepository; Alzheimer’s Disease
Neuroimaging Initiative
Carter, Hochberg/University of California San
Diego
ExRNA Biomarkers for Human Glioma Central nervous system/
CSF and plasma
UCSD Biorepository
Van Keuren-Jensen, Huentelman, Adelson,
Kalani/Translational Genomics Research
Institute
ExRNA Signatures Predict Outcomes after
Brain Injury
Central nervous system/
CSF and plasma
Barrow Neurological Institute Biorepository; Biologic
Materials Availability Program at Phoenix Children’s
Hospital
Weiner, Gandhi/Brigham and Women’s Hospital Circulating MicroRNAs As Disease
Biomarkers in Multiple Sclerosis
Central nervous system/
plasma
CLIMB MS Cohort
Tuschl, Suthanthiran/Rockefeller Clinical Utility of Extracellular RNA As Marker
of Kidney Disease Progression
Renal/urine Multiple Longitudinal Cohorts
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(PCR) based assays. On average, HCC cells released a
larger amount of exRNA compared to normal hepatocytes
(average of 1.23% vs. 0.55% of total donor cell RNA).
For selected samples, expression of 800 miRNAs and
33 lncRNAs was also analyzed using NanoString. These
analyses identified 14 lncRNAs and 33 miRNAs that were
selectively increased in HCC cells compared to normal
hepatocytes, and enriched within exRNA preparations
from these cells. The expression of selected non-coding
RNA was then examined using different assay platforms,
namely quantitative PCR (qPCR), NanoString, or droplet
digital PCR (ddPCR) to directly compare these assays
for the detection of extracellular non-coding RNA. Three
miRNA (miR-25, miR-302d and miR-612) were not
detected by qPCR assays but were identified in exRNA
preparations from all HCC cells, as well as from serum
obtained from 6 patients with HCC by NanoString and
ddPCR. Sensitive assays based on quantitative and digital
PCR for detection of exRNA are now being developed and
validated for use in the UH3 validation studies.
Biomarkers of gastric cancer
In ‘‘Clinical Utility of Salivary ExRNA Biomarkers for
Gastric Cancer Detection’’ (TR000923), Dr. Wong and
colleagues at the University of California Los Angeles take
a similar approach to developing biomarkers for early
detection in gastric cancer. A key difference in this study is
the focus on saliva as the source of exRNA biomarkers.
Dr. Wong and colleagues are particularly suited to this
effort, since their research group discovered the presence
of a transcriptome in cell-free saliva (CFS) in 2004 (5).
More than 3,000 different types of mRNAs were discov-
ered by gene expression-based microarrays. Of the 3,000
Fig. 1. ERCC biomarker groups.
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mRNAs, 185 mRNAs were consistently detected in
healthy subjects, forming what is now called the normal
salivary core transcriptome (NSCT) (6). Since then, saliva
has become an emerging biofluid poised for translational
and clinical applications. Dr. Wong’s group has established
a robust platform for studying salivary mRNA that invol-
ves extraction, purification, amplification, high-throughput
(HT) microarray screening and most recently a direct
assay for salivary transcriptome analysis without the need
for mRNA extraction (7). They have also developed
statistical and informatics capabilities that are customized
for salivary biomarker discovery and validation (8). The
nature, origin and characterization of salivary mRNAs
have been studied extensively. These include salivary
exRNA characterizations (9) including cDNA library
analysis (10), direct salivary transcriptome analysis (7),
with the most recent comprehensive sequencing platform
revealing 3 major class of exRNA in saliva: mRNA,
miRNA (11) and snoRNA (12). These accomplishments
provide the scientific foundation for utilizing saliva for
clinical applications, specifically for early detection and
diagnosis. Salivary extracellular transcriptomic biomar-
kers have been successfully applied for detection of oral
squamous cell carcinoma (OSCC) (5,13), Sjo¨gren syn-
drome (14), pancreatic cancer (15), breast cancer (16), lung
cancer (17) and ovarian cancer (18), strengthening the
plausibility of using this approach to biomarkers for
gastric cancer.
The key rationale for selecting gastric cancer in this
study is the existence of a biorepository of saliva samples
from 500 cases of gastric cancer and non-gastric cancer in
collaboration between Dr. Wong’s group and the Samsung
Medical Center. These are carefully annotated clinical
samples that are procured based on the prospective-
specimen-collection and retrospective-blinded-evaluation
(PRoBE) design using a standard operating procedure
(SOP). This existing clinical resource allowed for the im-
mediate exploration of biomarker discovery in the UH2
phase, followed by a definitive validation of discovered
biomarker candidates using independent clinical samples
that will permit individual marker validation, panel
configuration and then validation of the biomarker panel
using additional independent clinical samples.
Biomarkers of gastric cancer: approach
In the UH2 phase, comprehensive RNA sequencing
(RNA-Seq) will be performed on 100 randomly selected
gastric cancer saliva samples and 100 randomly selected
non-gastric cancer matched control subjects. Candidate
salivary exRNA biomarkers will be selected and ranked,
and then verified using qPCR in the discovery set of
clinical samples (100/100). Only verified candidates will
be advanced to UH3 phase for validation. In the UH3
phase, additional saliva samples will be accrued from 750
gastric cancer patients and 750 non-gastric cancer mat-
ched controls. Individual biomarkers will then be vali-
dated by association (odds ratio) with gastric cancer, and
a multimarker prediction model will be constructed for
diagnosis of gastric cancer using saliva from 500 ran-
domly selected gastric cancer and 500 randomly selected
non-gastric cancer matched control subjects. Validated
individual salivary RNA biomarkers will be configured
to the most discriminatory panel by logistic regression
analysis. Finally, the newly configured salivary exRNA
biomarker panel for gastric cancer detection will be vali-
dated in an independent set of 250 gastric cancer and
250 non-gastric cancer matched control subjects.
Biomarkers of gastric cancer: progress to date
RNA isolation techniques were optimized for salivary
RNA isolation efficiency by systematically comparing
6 commercially available kits with optimized protocols:
(a) organic extraction method (Trizol LS); (b) spin filter
based method [QIAamp Viral (Qiagen), NucleoSpin
(Clontech) and miRVana (Life Technologies)]; and (c)
combined method of organic extraction and spin filter
clean up (miRNeasy Micro Kit (Qiagen), Quick-RNA
MicroPrep (Zymo Research). The quantity and size
distributions of the resulting RNA samples were assessed
using RiboGreen reagent and Bioanalyzer, respectively,
with the best yields from NucleoSpin and miRNeasy
Micro kits. qPCR and ddPCR were used to determine
the efficiency of long and small RNA isolation from each
kit; the studies revealed that the miRNeasy micro Kit and
NucleoSpin are the best kits in yielding small RNAs at the
same time as long RNAs.
Library construction kits were also compared to eva-
luate the performance of alternative methods for library
construction, using multiple commercially available kits
targeting different types of RNA. The results showed that
the New England Biolabs (NEB) small RNA-Seq kit and
the NEB directional RNA-Seq kit generated the most
reproducible, sensitive and affordable profiling of respec-
tive types of mRNAs and ncRNAs in CFS. As of today, a
total of 200 small RNA libraries and 200 long RNA
libraries have been constructed with extracted salivary
exRNA samples from 100 gastric cancer patients and 100
non-gastric cancer matched controls. All libraries were
sequenced using Illumina HiSeq 2,000 sequencers at the
UCLA core facility.
Comprehensive profiling of exRNAs in human CFS
from healthy individuals was optimized according to
previous methods (19). A total of 127418 miRNAs and
32109 piwi-interacting RNAs (piRNAs) were detected in
CFS, and the abundance of CFS miRNAs was highly
similar to that in other body fluids based on a compa-
rative analysis of public datasets of different origins.
Intriguingly, piRNAs are more abundant than those in
most intracellular or extracellular samples but similar to
those in embryonic stem cells and skin cells. Furthermore,
Development of exRNA as biomarkers
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a customized bioinformatics method identified 400 circu-
lar RNA (circRNAs) in CFS, representing the first global
characterization and experimental validation of circRNAs
in any type of extracellular body fluid (19).
Biomarkers of myocardial risk and injury
Cardiology is another medical subspecialty that already
employs protein biomarkers in clinical practice, with the
use of serum creatine phosphokinase (CPK) and tro-
ponin in the diagnosis of myocardial infarction (MI) as
the best-established examples. Two of the grants in this
program seek to expand the search for useful biomarkers
of cardiovascular disease (CVD) to include exRNAs.
Biomarkers of post-MI risk
In ‘‘Plasma MiRNA Predictors of Adverse Mechanical
and Electrical Remodeling after Myocardial Infarction’’
(TR000901), Drs.Das, Shah,Danielson, Kwong,Rosenzweig
and Sabatine at Beth Israel Deaconess and Brigham and
Women’s Hospital proposed to identify plasma RNA
markers which distinguish ‘‘good’’ from ‘‘bad’’ cardiac
remodellers after MI, with the goal of using such markers
to stratify risk of adverse outcomes and thereby target
intervention to individuals at highest risk. Dramatic ad-
vances in the management of acute coronary syndromes
(ACS) have led to a significant decline in acute mortality
from MI. However, there continues to be significant mor-
bidity and mortality from the sequelae of MI. The adverse
mechanical and electrical remodelling that occurs subse-
quent to an MI underlies the development of heart failure
(HF) and sudden cardiac arrest (SCA), respectively. With
300,000 cases of SCA and 550,000 cases of HF diagnosed
annually (20), these adverse outcomes in post-MI patients
represent a leading cause of mortality in the United States
and a significant economic burden. Although prophylac-
tic therapy for SCA with implantable defibrillators and
early treatment of HF with medications or devices impro-
ves clinical outcomes, these therapies are deployed based
on markers that are inadequately robust to identify all
patients at risk (2123) (e.g. overall left ventricular func-
tion) or require invasive study (electrophysiology study).
In addition, only a minority (25% per year) of patients
who qualify for defibrillator implantation have ventricular
arrhythmias resulting in SCA. Therefore, development of
novel markers of adverse remodelling may improve the
sensitivity and specificity for predicting adverse outcomes
post-MI and may help reduce morbidity and mortality.
Towards this end, Das and colleagues have conducted
studies to identify, validate and investigate the pathobio-
logy of specific exRNAs involved in myocardial remodel-
ling in HF. In a registry of patients with HF undergoing
biventricular pacemaker implantation (a therapy for HF)
(24), they identified a miRNA signature of beneficial
response to pacing therapy based on screening a panel
of known miRNAs. Analysis of the data with a non-
hierarchical clustering algorithm demonstrated that re-
sponders to coronary reperfusion therapy (CRT) could
be segregated from non-responders and that 5 candidate
miRNAs were significantly different between the two
groups. Of these miRNAs, miR-30d was identified as
dysregulated in canine models of HF (25) (with improve-
ment after biventricular pacing). Furthermore, in a cohort
of over 50 patients with HF undergoing biventricular pac-
ing, miR-30d was independently associated with favour-
able response in cardiac function after biventricular pacing.
These data suggested that the use of validated animal
models in prioritizing biomarkers based on a mechanistic
role in disease pathology may be useful in yielding robust
candidates that validate prospectively. The overall goal
of this proposal is to perform an unbiased profiling of
circulating plasma exRNAs to develop a signature of
adverse mechanical and electrical remodelling in post-MI
patients, complemented by in-depth animal models to help
identify the most robust markers for further investigation
and validation. In addition, these signatures will then
be developed into a rapid, multiplex digital PCR-based
assay for clinical translation. The exRNA profiles will
be readily available to the scientific community and may
provide therapeutic targets that may be exploited in syn-
ergy with other investigators. These results will lay the
foundation for a novel strategy of risk-stratification for
post-MI patients that will allow for identification of
patients at high risk of adverse electrical and mechanical
remodelling, who may benefit from more aggressive moni-
toring and interventions with medications and defibrillators.
Biomarkers of post-MI risk: approach
To achieve the goal of identifying novel circulating plasma
miRNAs that are markers for electrical and mechanical
remodelling in post-MI patients, this study will utilize
patients with blood collection and cardiac magnetic
resonance imaging (for cardiac structure and function)
24 weeks post-MI and subsequently 6 months post-MI.
Within this cohort, matched populations of individuals
can be defined with beneficial and poor cardiac remodel-
ling (by cardiac volumes and function; mechanical
remodelling) and those who have died from suspected
or known SCA (electrical remodelling). For biomarker
discovery, next-generation sequencing approaches (RNA-
Seq) will be used, in order to take advantage of the ability
to detect novel exRNAs and low abundance transcripts
relative to a traditional microarray platform (26). In the
next phase, 2040 candidate miRNAs will be carried
forward to a validation phase, wherein (a) The biological/
mechanistic significance of each candidate will be con-
firmed by use in ischemia-reperfusion models of murine
MI; (b) Larger validation studies will be conducted in a
cohort of more than 270 individuals (PROSPECT-CMR,
PI Dr. Raymond Kwong) with concurrent cardiac mag-
netic resonance imaging and blood collection early and
Joseph F. Quinn et al.
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late post-MI (to define roles in remodelling and sudden
death susceptibility); and finally (c) The clinical signifi-
cance of these miRNA biomarkers will be validated in a
large cohort of over 4,000 patients in the Thrombolysis in
Myocardial Infarction-36 study (TIMI).
Biomarkers of post-MI risk: progress to date
In concert with other NIH Extracellular RNA Communica-
tion Consortium (ERCC) members, Das and colleagues
have optimized RNA isolation from plasma, assessed the
influence of library preparation methods on RNA-Seq
reads and explored pipelines for RNA-Seq mapping and
analysis. Using these optimized techniques, RNA-Seq
on a sample of patients with favourable and poor left
ventricular remodelling post-MI has identified a signifi-
cant number of initial potential targets for validation.
Several miRNAs with known function in HF and CVD
have been detected, including miR-30d (in addition to
miR-423-5p; -92a; 451; 21; and 378). In addition, further
mechanistic studies on miR-30d have confirmed its
role in cardioprotection (against apoptosis and hypoxia-
mediated cardiac stress). In the coming months, biomar-
ker discovery will be completed, and the project will
proceed to validation in animal models and then in patients
carefully phenotyped by cardiac magnetic resonance
early and late post-MI, and in a larger clinical study of
patients in the TIMI group. This research occurs across
the backdrop of a renaissance of exRNA research in
CVD (2733). Multiple groups have embarked on the
task of identifying, validating and proving the biological
significance of a host of exRNAs implicated in cardiac
remodelling and risk. By using a discovery cohort that
consists of patients with careful phenotyping of electrical
and mechanical remodelling, and prioritizing candidates
based on possible functional roles in cardiac remodelling,
these studies are likely to identify novel prognostic bio-
markers and provide additional groundwork for a better
understanding of the role of non-coding RNAs in heart
disease.
Biomarkers of asymptomatic atherosclerosis and
pre-MI risk
In ‘‘Extracellular RNAs: Biomarkers of Cardiovascular
Risk and Disease’’ (TR000921), Drs. Freedman, Tanriverdi
and colleagues at the University of Massachusetts Medical
School extend the search for biomarkers of cardiovascular
risk into the population of asymptomatic individuals.
CVD and stroke are two of the leading causes of morbidity
and mortality among US adults and are strongly deter-
mined by CVD risk factors including hypertension, diabe-
tes, obesity, smoking and dyslipidemia. Specific exRNAs
regulate key processes central to the pathogenesis of CVD.
Several small human studies have associated exRNAs with
CVD and several of its risk factors. This project postulates
that circulating plasma levels of exRNAs (a) vary over
time even in disease-free individuals, (b) are associated
with the duration and burden of CVD risk factors, (c)
relate to subclinical atherosclerosis and (d) are useful
predictors of longitudinal changes in CVD risk factors
and incident CVD events.
Biomarkers of pre-MI risk: approach
Using the Framingham Heart Study (FHS) cohort, this
project will further examine and validate the diagnostic
and prognostic utility of exRNAs associated with CVD
and preclinical CVD phenotypes in the community and
in a hospitalized acute coronary syndrome sample. The
FHS is a community-based, prospective study of CVD
and its risk factors. Beginning in 1971, the offspring study
enrolled 5,124 participants who were the children of the
originalFHS cohort, and their spouses. All cohorts undergo
an examination at the FHS once every 48 years.
Cohorts have been remarkably densely phenotyped over
multiple prior examinations with a wide variety of non-
invasive tests of cardiovascular structure and function.
The UH2 phase will use an optimized non-commercial
isolation method for high-yield plasma RNA extraction.
Investigators conducted HT sequencing to identify known
and as-yet undiscovered circulating exRNAs, thereby
developing a broad panel of plasma-derived exRNA
biomarkers (including miRNA, piRNA and other non-
coding RNAs) in FHS participants. The specific goals are
to: (a) isolate exRNA from human blood plasma samples
using advanced fractionation methods (endosomes, pro-
teins, lipids) and develop methods optimized for HT and
robotic handling so as to transition to clinical populations,
(b) perform HT RNA-Seq on previously stored plasma
from FHS participants (Offspring Exam 8) including those
with/without CVD so as to identify an initial working
panel of 588 plasma-expressed exRNA sequences, con-
sisting of all those that appear to distinguish disease from
disease-free states, as well as a set of invariant normali-
zation controls, (c) use HT qRT-PCR assays to validate
and refine the initial working panel of candidate exRNA
biomarkers identified by RNA-Seq in Goal 2. In this
study, exRNA levels (588) will be quantified in samples
of stored plasma from 2,914 participants of the FHS
Offspring Cohort (8th visit). Data from these qRT-PCR
profiles will be analyzed with other clinical data (risk fac-
tors and contemporaneously measured mRNA/protein
expression) previously obtained and available for all
participants and (d) using data from these goals, begin
development of target-specific probes attached to com-
mercially developed hydrogel particles and determine
the feasibility of measuring specific panels of exRNA in
clinical samples.
Because it is necessary to prioritize exRNAs for further
examination, 40 samples from the FHS cohort (N10
each of males and females with and without CVD) were
selected to be sequenced, and a large set of unbiased
exRNAs has been identified. After RNA sequencing of
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40 FHS participants and identification of targets, gene
expression measurements will be performed using HT
qRT-PCR. Plasma exRNA expression will be examined
in almost 3,000 samples, and relationships will be exami-
ned between exRNA expression and cardiovascular risk
factors, as well as measured subclinical atherosclerotic
disease phenotypes (including coronary artery calcification;
and carotid intimal medial thickness) and to prevalent
CVD (n435; including MI, unstable angina, sudden
death, HF and stroke). The final portion of the UH2
project will use a method that utilizes unique post-
hybridization ligation to fluorescently label bound miRNA
targets. Based on findings from the efforts described above,
the investigators will develop multiplexed assays to further
evaluate clinical samples.
Biomarkers of pre-MI Risk: progress to date
The investigators have sequenced 20 CVD and 20 mat-
ched non-CVD plasma samples using an Ion Proton
platform in-house in our laboratory. Sequencing data
were processed in the Genboree Sequencing pipeline with
the assistance of Drs. Gerstein, Rozowsky, Navarro and
Kitchen from Yale University, and comparative analysis
was performed. These data show that, (a) plasma RNA-
Seq analysis shows that large numbers of miRNAs, small
nucleolar RNA (snoRNAs), transfer RNA (tRNAs) and
piRNAs exist in human plasma samples, (b) non-human
RNAs are also detected by using the small exRNA-Seq
pipeline on Genboree. Although only one miRNA was
discriminatory between the groups, the data provide an
expansive list for further study in the rest of the Offspring
8 cohort. Based on these data, the investigators are
measuring close to 700 exRNAs in the full FHS Offspring
8 Cohort as described above. RNA isolations of these sam-
ples are completed and HT RT-PCR is being performed.
Biomarkers of placental dysfunction
Placental dysfunction, most commonly manifested as pre-
eclampsia or intrauterine growth restriction, is an impor-
tant cause of maternal and foetal morbidity and mortality
in both the developing and developed world. It is thought
that placental dysfunction arises from abnormal tropho-
blast differentiation and/or invasion, events that occur in
the first trimester of pregnancy, but become clinically
apparent only in the late second and third trimesters. Opti-
mal surveillance and management of placental dysfunc-
tion, as well as the development of effective therapies, have
been hampered by the lack of methods for early and accu-
rate identification of pregnancies at risk for this disorder.
Biomarkers of placental dysfunction
In ‘‘ExRNAs for Early Identification of Pregnancies at
Risk for Placental Dysfunction’’ (TR000906), Dr. Laurent
and colleagues at UC San Diego aim to develop exRNA-
based methods that can be used in early gestation to
identify pregnancies that will develop clinically significant
placental dysfunction.
Biomarkers of placental dysfunction: approach
Building upon knowledge that exRNAs of placental
origin can be found in the maternal circulation, the first
phase of the project is aimed at identification of candi-
date exRNA biomarkers from a prospectively collected
high-risk cohort, the UCSD Placental Dysfunction Study.
In the second phase, these candidate biomarkers will then
be validated in a separate average-risk cohort, the 5,500
member Proteomic Assessment of Preterm Risk (PAPR)
cohort from Sera Prognostics. Finally, a Clinical Labora-
tory Improvement Amendments (CLIA) certified assay
will be developed and applied in a pilot randomized con-
trol trial to assess the clinical and cost impact of screen-
ing a general obstetric population for risk of placental
dysfunction, and referral of screen-positive patients to a
higher level of surveillance.
Biomarkers of placental dysfunction: progress to date
In initial experiments, the investigators have used serum
samples from healthy non-pregnant and healthy pregnant
women collected at different gestational ages to select the
RNA isolation and small RNA sequencing method for
use in samples from the UCSD Placental Dysfunction
Study. Preliminary data show that differences between
non-pregnant and pregnant samples become significantly
more pronounced in the late second trimester, so biomarker
discovery will be performed on samples collected at
24 weeks of gestation. Thus far, the research team has com-
pleted enrolment of 300 high-risk subjects in the UCSD
Placental Dysfunction Study. A total of 160 of these
subjects have delivered and had their clinical outcomes
adjudicated. From these adjudicated subjects, small RNA
sequencing has been performed for 20 cases and 32 controls.
Analysis of this dataset is in process, while clinical outcome
data from the remainder of the subjects is being collected
for selection of a second set of samples for analysis.
Biomarkers of central nervous system disease
Four of the grants probe the central nervous system,
examining exRNA content of CSF and plasma. CSF has
the advantage of being in direct contact with the central
nervous system, so the blood brain barrier does not pre-
vent the CSF from reflecting extracellular CNS biology.
However, as CSF collection is an invasive procedure,
patients prefer peripheral blood sampling consequently
resulting in larger numbers of subjects included in a given
study. One proposal studying neurodegenerative disease
relies primarily on CSF, two other proposals examined
both CSF and plasma in brain tumours and intracerebral
haemorrhage, while the 4th study relies on plasma
samples alone, since multiple sclerosis is known to be
reflected in immune cells from the peripheral blood.
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Biomarkers of neurodegenerative disease
In ‘‘Clinical utility of MicroRNAs as Diagnostic Biomar-
kers of Alzheimer’s Disease’’ (TR000903), Drs. Saugstad,
Quinn and colleagues at Oregon Health and Science
University examine the utility of exRNA in CSF from AD
patients. AD, characterized by brain pathology including
amyloid plaques and neurofibrillary tangles, is the most
common neurodegenerative disease, affecting 1015% of
individuals between age 75 and 85, and up to 50% of those
over age 85. As the population ages, AD is becoming more
prevalent and represents a looming public health crisis,
described by some as ‘‘the disease of the century.’’ The
need for improved biomarkers of AD is substantial, as the
clinical diagnosis of AD is confirmed in only 90% of
patients with overt dementia, meaning that clinical trials
are confounded by mis-diagnosis in 10% of the popula-
tion, even in the case of established dementia. The need is
even more acute as interventions are applied in prodromal
states like mild cognitive impairment (MCI) (34) or even
pre-symptomatic or latent AD (35). Nuclear medicine
imaging of cerebral amyloidosis has been an important
and useful advance in this area, but these PET scans
are prohibitively expensive and are limited to the single
feature of amyloid deposition. CSF protein biomarkers of
classical AD pathology, namely beta amyloid 142 (the
chief component of plaques) and total and phosphory-
lated tau (the chief component of neurofibrillary tangles)
have also been utilized to enrich study populations for
clinical trials, but the sensitivity and specificity are not
optimal, and variability across laboratories has also been
problematic (34). The plausibility of developing exRNAs
as AD biomarkers is supported by several exploratory
clinical studies (3640). However, variability in results
reported to date illustrates the importance of attending to
details of sample collection, RNA isolation and RNA
quantification, in addition to careful phenotyping of the
subject population. This project consequently uses CSF col-
lected under standardized conditions, from carefully char-
acterized subjects sampled in a uniform morning fasting
condition, with specimens aliquoted in uniform fashion,
snap frozen and stored at -80 degrees until use (41).
Biomarkers of neurodegenerative disease: approach
The UH2 phase will utilize CSF banked at the Oregon
Alzheimer’s Disease Center (OADC) Biorepository for the
‘‘discovery’’ phase of the project. The expression of all
known human miRNAs will be determined using Taqman
miRNA qRT-PCR arrays on existing CSF samples isola-
ted from healthy subjects and AD patients in the OADC.
Candidate biomarkers will be determined by statistical
analysis and then verified using customized arrays with the
discovery sample. The verified miRNA biomarkers will
then be validated in a new set of CSF samples isolated from
healthy subjects and AD patients obtained from the
OADC. The UH3 phase will utilize CSF from the NIA-
funded Alzheimer’s Disease Neuroimaging Initiative
(ADNI) to test the performance of candidate biomarkers
in the ADNI CSF bank of approximately 100 asympto-
matic elderly, 200 MCI and 100 AD subjects.
Biomarkers of neurodegenerative disease: progress
to date
Preliminary studies were performed to optimize RNA
isolation and to determine the effects of storage time
and CSF gradient upon outcomes. Total RNA recovered
from samples stored for 1 year, 5 years and 10 years was
comparable, with no indication of loss of total RNA over
time. Expression of miRNA was comparable in samples
that were stored for different lengths of time, with 206
miRNAs from an array of 756 probes detected in CSF
at all three time points. These preliminary experiments
were important for confirming that banked, frozen CSF
samples stored for up to 10 years would be suitable for this
work, optimizing the number of samples available for the
discovery phase. After these preliminary methodological
studies, CSF miRNA expression was compared in 47 AD
and 47 healthy control subjects, matched for age and sex.
A panel of 19 candidate miRNAs that are differentially
expressed in the two groups has been identified for further
analysis. Combinations of 34 miRNA distinguish AD
from control subjects more effectively than individual
miRNAs. Interestingly, most of the miRNAs distinguish-
ing between the two groups are downregulated in AD
compared to healthy control subjects. Confirmation of
this AD signature is currently being performed using a
panel of miRNAs in custom qRT-PCR assays. The UH3
validation phase in ADNI samples is scheduled to begin
in fall 2015.
Biomarkers of brain tumours
In ‘‘ExRNA Biomarkers for Human Glioma’’
(TR000931), Drs. Carter, Hochberg and colleagues at
UC San Diego are testing the hypothesis that exRNA in
CSF will include markers that will help diagnose and
subtype primary brain tumours. Glioblastoma (GBM) is
the most common and aggressive primary brain tumour,
with a 2-year survival rate less than 20% (42). Several
subtypes of GBM have been identified (4346) and in some
cases subtyping of glioma can guide treatment decisions.
Since MRI imaging does not adequately distinguish GBM
from other tumours, diagnosis and subtyping currently
depend on biopsy and tissue diagnosis. However, brain
biopsy is challenging in some cases due to inoperable
localization of lesions, and the diffusely infiltrative nature
of GBM makes it difficult to ensure that any biopsy will
include representative tissue. Indeed in the United States,
it is estimated that one in 5 brain tumour patients never
undergoes a diagnostic operation and only 30% experi-
ence surgery that benefits their outcome. Biopsies do not
improve morbidity or survival, inadequately predict
histopathologic diagnosis and seldom take into account
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topographic tumour heterogeneity (4749). Current
non-surgical diagnostic tests neither predict resistance
to therapy nor provide metrics of molecular changes
within the tumour and seldom distinguish tumour
progression from tumour necrosis (5053). Non-invasive
GBM-specific biomarkers would provide the clinician
and patient with a window into tumour diagnosis and
molecular structure with a high degree of sensitivity and
specificity, with the ultimate goal of developing targeted
therapeutic agents based on these diagnostics and utiliz-
ing the ‘‘liquid biopsies’’ to assess drug efficacy.
The search for informative biomarkers in CSF has
recently turned to exRNA, which is promising for several
reasons. RNA in EVs is stable in biofluids where it is likely
protected from RNases, can be isolated from serum and
CSF, and can be easily detected from small copy numbers
with high sensitivity using reverse transcription PCR (54).
In addition, tumour derived EV RNAs (especially miRNA
and mRNA) can be amplified up to 100-fold within target
cells and are thus likely in the microenvironment. And
finally, multiple glioma-specific EV RNA amplifications
and mutations have been identified as biomarkers (5458).
These include epidermal growth factor receptor variant
III (EGFRvIII, a highly specific deletion mutation found
in 2025% of GBMs) and isocitrate dehydrogenase 1 and
2 (IDH1/2) mutations (found in 10% of GBMs). Each is
associated with GBM molecular subtypes, correlates with
patient survival and can be targeted with specific therapies
(45,46,55,5961).
Biomarkers of brain tumours: approach
Key milestones of this project include (a) collection and
banking of biospecimens to support pilot studies and
then cohort studies, (b) determination of the optimal plat-
form for isolation and analysis of EV RNA gene products
and (c) identification and further assessment of the most
promising EV RNA GBM biomarkers. A summary of
this work to date is provided below.
Biomarkers of brain tumours: progress to date
To date, specimen collection and banking has resulted
in an established tissue-fluid biorepository which houses
over 4,000 specimens from over 600 subjects, the majority
with brain tumours (62). This facility employs strict SOPs
in accordance with International Society of Extracel-
lular Vesicles recommendations for sample collection and
storage, and utilizes bar-coded specimen tracking tech-
nology adapted to multi-institutional collaborations. The
optimal platform for sample processing and analysis has
been determined, and a collaborative CSF group is con-
ducting comparative trials of EV RNA isolates using
multiple isolation kits, RNA assays and analytic techni-
ques. These systems are being compared for EV RNA
yield, purity and gene product detection. Identification
of the most promising candidate biomarkers resulted in
2 categories: (a) GBM-specific mutations (e.g. EGFRvIII
deletions and IDH1.132 point mutations) which may be
scored and analyzed as ‘‘present’’ versus ‘‘absent’’ and (b)
wild-type EV genes known to be quantitatively differen-
tially expressed in GBM, such as EGFR, IDH1 and pro-
moter methylated proteins. Thus, the expression of the
mutant growth factor receptor EGFRvIII provides for
differentiation of EVs from GBM and non-tumour tissue.
EGFRvIII RNA can be isolated from the serum at a level
approaching a sensitivity of 60% and specificity of 98% (63).
Similarly, human blood and CSF samples could provide a
predictive metric of treatment-induced changes (64). The
detection of single amino acid mutations is more difficult
given the vast background ‘‘noise’’ of wild-type sequences,
a difficulty which has resulted in the use of high-
resolution techniques such as BEAMing (beads, emul-
sion, amplification, magnetics) PCR and ddPCR. These
techniques can detect mutations as rare as 0.01% or as
few as 20 copies. These methods identified mutant IDH1
mRNA in CSF-derived EVs from patients with mutant
IDH1 gliomas, and established that patients with tumours
have higher levels of CSF and serum EV mutant IDH1
mRNA than healthy controls (65).
Expression changes in the EV RNA levels of wild-type
genes obligates quantitative analyses as opposed to ‘‘pre-
sent or absent’’ scoring. Methylated promoters of nucleo-
tide repair enzymes, such as O6-methylguanine methyl
transferase (MGMT), are EV biomarkers of interest due
to their link to temozolomide resistance (66). The study
team has recently demonstrated that expression of 2
miRNAs (miR-603 and miR-181d) inversely correlated
with MGMT expression and that a combined index of
these molecules can serve as a proxy for MGMTexpression
(67). Extrapolating from these findings, EV RNA sam-
pling of miR-603 and miR-181d, or similar regulatory
molecules, has the potential to predict GBM temozolo-
mide resistance. Expression levels of EV wild-type EGFR
have also shown promise as a stand-alone or multipanel
biomarker for GBM (64).
There are unique challenges of working with EV
RNAs in a world without clear consensus. Yields of EV
RNA vary based on the gene of interest and biofluid
analyzed, and RNA from specific genes may be as rare
as 40 copies/mL in these fluids (65). As an additional
challenge, reference transcripts or ‘‘housekeeping genes’’
commonly used for qPCR (including GAPDH and 18S
rRNA) may be under-expressed in biofluids such as CSF
and vitreous and have not been defined for EV-associated
miRNA. As an alternative, these investigators normalize
the absolute EV miRNA expression to input EV number
(determined via Nanoparticle Tracking Analysis [NTA])
(58). Using this technique, they recently demonstrated that
quantification of EV miR-21 (an miRNA highly over-
expressed in GBM) was able to prospectively distinguish
CSF derived from GBM and non-oncologic patients
in an independent cohort analysis (58). Thus, EV RNA
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biomarkers have clinical potential for GBM diagno-
sis, subtype assessment, prognostication and disease
progression tracking. The establishment and continued
growth of a biospecimen repository supported by the
NIH plays a central role in efforts towards biomarker
discovery and validation. These technologies will enable
GBM treatments tailored to specific ‘‘liquid biopsy’’
tumour profiles and the collaboration of drug designers
to implement novel therapeutics.
Biomarkers of intracranial haemorrhage
In ‘‘ExRNA Signatures Predict Outcomes After Brain
Injury’’ (TR000891), Drs. Van Keuren-Jensen and
Huentelman at the Translational Genomics Research Insti-
tute, in collaboration with Drs. Kalani, Spetzler, Arango
and Adelson at the Barrow Neurological Institute, St.
Joseph’s Hospital and Medical Center (Kalani, Spetzler)
and the Barrow Neurological Institute at Phoenix Chil-
dren’s Hospital (Arango, Adelson), examined exRNA in
2 devastating cerebrovascular events in need of bio-
markers for prediction of risk and targeting of therapy:
subarachnoid haemorrhage in adults (aSAH) and intra-
ventricular haemorrhage (IVH) in children. This study is
in collaboration with Drs. Michael Lawton (UCSF) and
Samuel Cheshier (Stanford). In adults, aSAH occurs in
1015 people per 100,000 every year. The risk for aSAH
rises with age and accounts for 17% of all strokes.
Cerebral vasospasm is a recognized and poorly understood
complication for many patients who have aSAH. Severe
vasospasm can lead to ischemia, permanent neurological
damage and death. Vasospasm develops approximately
24 days after initial aSAH, providing an opportunity for
early diagnosis and potential intervention to blunt the
cascades of secondary injury caused by this phenomenon.
In children, IVH is a significant complication of premature
birth. With improved preterm infant survival, there is
increased incidence of severe IVH and the potential for
lifelong neurodevelopmental deficits. Babies who develop
hydrocephalus as a result of IVH often require a per-
manent ventriculoperitoneal (VP) shunt. Approximately
one-third of babies with IVH develop post-haemorrhagic
hydrocephalus, and 15% require a VP shunt. An improved
understanding of the pathophysiological mechanisms at
work in this patient population may prevent unnecessary
interventions, decrease short- and long-term morbidity,
and decrease the cost of care. Both aSAH and IVH have
very specific temporal courses and represent a substantial
opportunity to identify biomarkers and interventions
that may impact patient health. In the case of brain
injury, the timing of intervention is of the utmost
importance to minimize the degree of secondary neuro-
logical insults and delayed neurological deficits. Aggres-
sive treatments are contraindicated in patients who will
recover with close monitoring and standard care. While
aggressive treatments do exist for patients who develop
complications of secondary injury cascades, these inter-
ventions are neither benign nor cheap and are frequently
initiated only after the pathways of secondary injury are
in full effect.
Although 98% of the human genome does not encode
proteins, 90% of the genome is likely transcribed (68);
therefore, evaluation of the full transcriptome is critical.
ExRNAs are enriched for non-coding, novel, endoge-
nous mediators of mRNA post-transcriptional regulation,
usually acting through gene silencing (69). Non-coding
RNAs (ncRNAs), including miRNAs, have been found
to play a role in most cellular processes and can have
very specific temporal, spatial and cell-specific expression
(70,71). More ncRNAs are enriched or uniquely expres-
sed in the central nervous system than anywhere else
in the body, and many RNAs are temporally expressed
during neurodevelopment and normal aging (72,73).
More importantly, the abnormal expression of ncRNAs
has been detected in cellular dysfunction and disease,
including ischemia, stroke and traumatic brain injury
(7477). The use of exRNAs as a sensitive readout of
changing pathophysiological conditions underlying tem-
porally defined brain insults could save thousands of lives
each year and significantly improve the quality of patient
life following intracranial haemorrhage.
Biomarkers of intracranial haemorrhage: approach
In the UH2 phase, CSF and plasma samples from aSAH
patients were collected on days 17 of their stay in the
intensive care unit, while CSF and plasma from infants
with IVH were collected at 12 weeks in the neonatal
intensive care unit. The miRNA profile in these samples
was described using small RNA sequencing approaches.
The whole transcriptome was sequenced in a subset of
these samples. The investigators have sequenced 500
small RNA samples and 250 whole transcriptome
samples and are currently analyzing the data and validat-
ing the RNA targets using a second platform. In the UH3
phase, the research team will sequence the samples from an
additional cohort to increase the numbers of subjects with
varying degrees of haemorrhage and stroke severity. They
will then test platforms for rapid detection of the RNA
profile in order to return results to the clinician as quickly
as possible. The goal is to achieve accurate and prognostic
profiling as close to real time as achievable.
Biomarkers of intracranial haemorrhage: progress to date
Investigators have profiled the blood and CSF of patients
with haemorrhagic strokes in search of biomarkers that are
associated with robust activation of secondary injury
pathways and poor outcomes. An effective exRNA bio-
marker would also be a means to quickly evaluate treat-
ment and help modify therapeutic approaches. Total
exRNA (whole transcriptome as well as miRNAs) is being
examined in the blood and CSFof patients with aSAH and
IVH. Whole transcriptome sequencing with the addition
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of small RNA sequencing has permitted close examination
of exRNA content in both biofluids and to monitor
changes associated with patient outcome. For the aSAH
patients, preliminary analysis has identified differentially
expressed RNAs that cluster the patients into outcome
categories 2 days prior to current clinical vasospasm
detection methods. The analysis for the IVH patients is
still ongoing.
Biomarkers of multiple sclerosis
In ‘‘Circulating MicroRNAs as Disease Biomarkers in
Multiple Sclerosis’’ (TR000890), Drs. Weiner, Gandhi and
colleagues at Brigham and Women’s Hospital address the
need for biomarkers for multiple sclerosis disease activity
to measure disease activity and for the purpose of pre-
dicting and monitoring response to disease-modifying
therapies. Although there is a better understanding of
immune mechanisms in MS and several FDA-approved
immune modulating therapies are available, a major chal-
lenge is to develop biomarkers that will allow a better
understanding of an individual MS patient, whether they
are a responder or non-responder to therapy, which medi-
cine is more effective, and the degree to which they may
be entering the progressive phase of disease. MiRNAs
provide a new avenue to understand immune regulation,
and the ability to measure them in the plasma or serum
makes them an ideal candidate as an immune biomarker.
Biomarkers of multiple sclerosis: approach
The UH2 phase of this project will take advantage of a
unique resource termed CLIMB (Comprehensive Longi-
tudinal Investigation of Multiple Sclerosis at Brigham
and Women’s Hospital). CLIMB is a cohort of over 2,000
MS patients that began enrolment 12 years ago and in-
cludes yearly blood samples, clinical exams and quanti-
tative MRI imaging. This proposal was based upon
preliminary data, suggesting that circulating miRNAs are
measurable in this MS cohort and are related to disease
stage, response to therapy and disability. The approach is
organized under the following aims: (a) identify miRNAs
that will act as diagnostic biomarkers by comparing MS
patients to healthy controls, patients with other neurolo-
gical diseases and patients with other autoimmune dis-
eases, (b) identify disease stage miRNA biomarkers by
comparing relapsing remitting (RRMS), secondary progres-
sive (SPMS) and primary progressive (PPMS) patients,
(c) identify prognostic miRNA biomarkers by determin-
ing the change in each miRNA over 2 years and assessing
which miRNAs are sensitive to long-term change in
disease status, (d) identify treatment response miRNA
biomarkers by comparing the baseline miRNA expres-
sion in responders and non-responders to treatment and
(e) identify disability miRNA biomarkers by correlating
miRNAs with EDSS and MRI measures of disease status.
Biomarkers of multiple sclerosis: progress to date
During Year 1, analysis of groups of 80 MS patients, 20
healthy controls and 50 other disease controls suggested
that miRNAs could provide potential biomarkers related
all the five categories: diagnostic, disease stage, prognostic,
treatment response and disability biomarker. During
the second year and UH3 phase of the study, selected
miRNAs will be validated on larger cohort of MS patients
and controls.
Biomarkers of renal disease
In ‘‘Clinical Utility of Extracellular RNA as Marker
of Kidney Disease Progression’’ (TR000933), Drs. Tuschl,
Suthanthiran, Bitzer, Putterman, Goilav and colleagues
propose to examine exRNA biomarkers for progression of
chronic kidney disease (CKD). CKD can result from high
blood pressure, diabetes, disorders of the immune system,
genetic defects and developmental disorders, and causes
early death from heart disease, infections and cancer.
Many CKD patients develop end-stage kidney disease
and need dialysis or kidney transplants. Recipients of
kidney transplants also are prone to CKD. Current tests
cannot predict which patients will have CKD that worsens
over time. Identifying CKD patients at risk for disease
progression could allow clinicians to treat patients earlier
and slow further decline in kidney function. It also could
help scientists develop therapies that prevent decline in
kidney function in patients at risk. This is the only project
in this group to focus on urine as the extracellular fluid
source of exRNA. The population studied includes adult
and paediatric cohorts, bothglomerular and non-glomerular
kidney disease, and both native and transplanted kidneys.
The research team will identify types of exRNA in the
urine of CKD patients and will determine if this approach
can identify patients at risk for worsening disease. They
plan to use these findings to develop a urine test that
clinicians can use to guide treatment of CKD patients.
Biomarkers of renal disease: progress to date
Renal involvement in systemic lupus erythematosus (SLE),
or lupus nephritis (LN), is associated with significant
morbidity and worse mortality than when this clinical
manifestation is not present. Furthermore, LN is more
common and severe when the onset of disease is during
childhood (78,79). Since it is believed that quicker diag-
nosis can lead to better clinical outcomes in LN, there is
tremendous interest in identifying early biomarkers for
kidney involvement. Putterman and his group demon-
strated that urinary miRNA deep-sequencing counts vary
by LN disease activity, in a manner suggestive of biomarker
potential (80). Specifically, they identified a set of
urinary miRNA that correlated with active versus inactive
LN in both adult and childhood LN, as well as urinary
miRNA that were indicative of particular LN histologic
classes. Interestingly, in a mouse model of immune com-
plex nephritis induced by passively transferred pathogenic
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antibodies, several dysregulated miRNAs present in the
serum of nephritic mice (identified by deep sequencing)
and which correlated with the peak of kidney involvement
were identical to those previously found in the urine of
lupus patients (81). Confirmation of the diagnostic utility
of these and other urinary miRNA in human lupus, and
investigating whether they have a pathogenic role in kidney
disease, is currently under active study.
Conclusions
The NIH Extracellular RNACommunication Consortium
(ERCC) and the UH2/UH3 funding mechanism have
allowed investigators from diverse medical subspecialties
to advance methodologies for describing and quantifying
exRNAs from a wide range of human body fluids with
the goal of exploiting this relatively new biological
phenomenon for the sake of improving clinical research
and care in each of these fields. While each of the projects
has spent a portion of the first year on method develop-
ment, all the projects have also successfully identified
candidate biomarkers for advancing to hypothesis testing
in the next phase. The dissemination of methodological
recommendations is in itself an important development in
any new field and will promote continued success both
within and beyond the ERCC.
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